NCT02506530

Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema

Contribution of an Endermologie LPG Cellu M6 Treatment in the Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema, During an Intensive Decongestive Treatment.

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 93 (actual)
• Sponsor: University Hospital, Toulouse · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will assess the benefit of LPG Cellu M6 in addition of intensive decongestive treatment in reducing secondary lymphoedema in breast cancer.

Detailed description

The main objective of the study is to assess the proportion of successfully treated patients (success rate). That is to say patients having a reduction of excess arm volume ≥ 30% after 5 days of three types of treatment for secondary lymphoedema : Group 1: standard intensive decongestive therapy for 5 days (bandages + manual lymphatic drainage). Group 2: standard intensive decongestive therapy (bandages + manual lymphatic drainage) + Cellu M6 for 5 days Group 3: Bandages + Cellu M6 for 5 days Symptomatic treatment of lymphoedema reference is intensive decongestive therapy including manual lymphatic drainage, compression of multicomponent bandaging, therapeutic exercise and skin care (HAS 2012 ISL International Society of Lymphology, 2013).

Conditions

• Lymphedema

Interventions

Type	Name	Description
PROCEDURE	intensive decongestive treatment	intensive decongestive treatment
DEVICE	Cellu M6	Use of Cellu M6

Timeline

• Start date: 2015-09-01
• Primary completion: 2018-12-01
• Completion: 2018-12-01
• First posted: 2015-07-23
• Last updated: 2025-12-05

Locations

1 site across 1 country: France